This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lacy, M. K.
Right arrow Articles by Nightingale, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lacy, M. K.
Right arrow Articles by Nightingale, C. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 1999, p. 672-677, Vol. 43, No. 3
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Pharmacodynamic Comparisons of Levofloxacin, Ciprofloxacin, and Ampicillin against Streptococcus pneumoniae in an In Vitro Model of Infection

Melinda K. Lacy,1,* Wen Lu,2 Xiaowei Xu,2 Pamela R. Tessier,2 David P. Nicolau,2,3 Richard Quintiliani,4 and Charles H. Nightingale4

Department of Pharmacy Practice, The University of Kansas Medical Center, Kansas City, Kansas 66160-7231,1 and Department of Pharmacy Research,2 Division of Infectious Diseases,3 and Office of Research Administration,4 Hartford Hospital, Hartford, Connecticut 06102-5037

Received 23 January 1998/Returned for modification 7 June 1998/Accepted 8 December 1998

The increasing frequency of penicillin-resistant pneumococcus continues to be of concern throughout the world. Newer fluoroquinolone antibiotics, such as levofloxacin, have shown enhanced in vitro activity against Streptococcus pneumoniae. In this study, the bactericidal characteristics and pharmacodynamic profiles of levofloxacin, ciprofloxacin, and ampicillin against four isolates of S. pneumoniae were compared by using an in vitro model of infection. Standard antibiotic dosing regimens which simulated the pharmacokinetic profile observed in humans were used. Control and treatment models were sampled for bacterial CFU per milliliter over the duration of each 24- or 48-h experiment. In addition, treatment models were sampled for MIC determinations and drug concentration. Regrowth of all isolates as well as an increase in MICs throughout the study period was observed in the ciprofloxacin experiments. A limited amount of regrowth was noted during levofloxacin therapy for one isolate; however, no change in MIC was detected for any isolate. Ampicillin showed rapid and sustained bactericidal activity against all isolates. In this study, ratios of effective fluoroquinolone area under the concentration-time curve (AUC):MIC values ranged from 30 to 55. Levofloxacin, owing to its larger AUC0-24 values, has excellent and sustained activity against different pneumococcal strains superior to that of ciprofloxacin.

* Corresponding author. Mailing address: Department of Pharmacy Practice, The University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160-7231. Phone: (913) 588-5314. Fax: (913) 588-2355. E-mail: mlacy{at}kumc.edu.

Antimicrobial Agents and Chemotherapy, March 1999, p. 672-677, Vol. 43, No. 3
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Homma, T., Hori, T., Sugimori, G., Yamano, Y. (2007). Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3810-3815 [Abstract] [Full Text]  
  • Louie, A., Brown, D. L., Liu, W., Kulawy, R. W., Deziel, M. R., Drusano, G. L. (2007). In Vitro Infection Model Characterizing the Effect of Efflux Pump Inhibition on Prevention of Resistance to Levofloxacin and Ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3988-4000 [Abstract] [Full Text]  
  • Odenholt, I., Cars, O. (2006). Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother 58: 960-965 [Abstract] [Full Text]  
  • DeRyke, C. A., Du, X., Nicolau, D. P. (2006). Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother 58: 601-609 [Abstract] [Full Text]  
  • Zhanel, G. G., James, J., Derkatch, S., Laing, N., Noreddin, A. M., Hoban, D. J. (2006). Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 58: 112-116 [Abstract] [Full Text]  
  • Kiser, T. H., Hoody, D. W., Obritsch, M. D., Wegzyn, C. O., Bauling, P. C., Fish, D. N. (2006). Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.. Antimicrob. Agents Chemother. 50: 1937-1945 [Abstract] [Full Text]  
  • Bhavnani, S. M., Passarell, J. A., Owen, J. S., Loutit, J. S., Porter, S. B., Ambrose, P. G. (2006). Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia. Antimicrob. Agents Chemother. 50: 994-1000 [Abstract] [Full Text]  
  • Jumbe, N. L., Louie, A., Miller, M. H., Liu, W., Deziel, M. R., Tam, V. H., Bachhawat, R., Drusano, G. L. (2006). Quinolone Efflux Pumps Play a Central Role in Emergence of Fluoroquinolone Resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50: 310-317 [Abstract] [Full Text]  
  • Noreddin, A. M., Haynes, V. L., Zhanel, G. G. (2005). Pharmacokinetics and Pharmacodynamics of the New Quinolones. Journal of Pharmacy Practice 18: 432-443 [Abstract]  
  • Cazzola, M., Matera, M. G., Donnarumma, G., Tufano, M. A., Sanduzzi, A., Marchetti, F., Blasi, F. (2005). Pharmacodynamics of Levofloxacin in Patients With Acute Exacerbation of Chronic Bronchitis. Chest 128: 2093-2098 [Abstract] [Full Text]  
  • Ginsburg, A. S., Lee, J., Woolwine, S. C., Grosset, J. H., Hamzeh, F. M., Bishai, W. R. (2005). Modeling In Vivo Pharmacokinetics and Pharmacodynamics of Moxifloxacin Therapy for Mycobacterium tuberculosis Infection by Using a Novel Cartridge System. Antimicrob. Agents Chemother. 49: 853-856 [Abstract] [Full Text]  
  • Van Wart, S., Phillips, L., Ludwig, E. A., Russo, R., Gajjar, D. A., Bello, A., Ambrose, P. G., Costanzo, C., Grasela, T. H., Echols, R., Grasela, D. M. (2004). Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections. Antimicrob. Agents Chemother. 48: 4766-4777 [Abstract] [Full Text]  
  • Regoes, R. R., Wiuff, C., Zappala, R. M., Garner, K. N., Baquero, F., Levin, B. R. (2004). Pharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens. Antimicrob. Agents Chemother. 48: 3670-3676 [Abstract] [Full Text]  
  • Bast, D. J., Yue, M., Chen, X., Bell, D., Dresser, L., Saskin, R., Mandell, L. A., Low, D. E., de Azavedo, J. C. S. (2004). Novel Murine Model of Pneumococcal Pneumonia: Use of Temperature as a Measure of Disease Severity To Compare the Efficacies of Moxifloxacin and Levofloxacin. Antimicrob. Agents Chemother. 48: 3343-3348 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
  • Florea, N. R., Tessier, P. R., Zhang, C., Nightingale, C. H., Nicolau, D. P. (2004). Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 1215-1221 [Abstract] [Full Text]  
  • Morrissey, I., Tillotson, G. (2004). Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother 53: 144-148 [Abstract] [Full Text]  
  • Pea, F., Pavan, F., Nascimben, E., Benetton, C., Scotton, P. G., Vaglia, A., Furlanut, M. (2003). Levofloxacin Disposition in Cerebrospinal Fluid in Patients with External Ventriculostomy. Antimicrob. Agents Chemother. 47: 3104-3108 [Abstract] [Full Text]  
  • Zinner, S. H., Lubenko, I. Yu., Gilbert, D., Simmons, K., Zhao, X., Drlica, K., Firsov, A. A. (2003). Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 52: 616-622 [Abstract] [Full Text]  
  • Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials. The Annals of Pharmacotherapy 37: 1478-1488 [Abstract] [Full Text]  
  • Scaglione, F., Mouton, J. W., Mattina, R., Fraschini, F. (2003). Pharmacodynamics of Levofloxacin and Ciprofloxacin in a Murine Pneumonia Model: Peak Concentration/MIC versus Area under the Curve/MIC Ratios. Antimicrob. Agents Chemother. 47: 2749-2755 [Abstract] [Full Text]  
  • Garrison, M. W. (2003). Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 52: 503-506 [Abstract] [Full Text]  
  • Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models. The Annals of Pharmacotherapy 37: 1287-1298 [Abstract] [Full Text]  
  • Greko, C., Finn, M., Franklin, A., Bengtsson, B. (2003). Pharmacokinetic/pharmacodynamic relationship of danofloxacin against Mannheimia haemolytica in a tissue-cage model in calves. J Antimicrob Chemother 52: 253-257 [Abstract] [Full Text]  
  • Firsov, A. A., Vostrov, S. N., Lubenko, I. Y., Drlica, K., Portnoy, Y. A., Zinner, S. H. (2003). In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1604-1613 [Abstract] [Full Text]  
  • Nicolau, D. P., Mattoes, H. M., Banevicius, M., Xuan, D., Nightingale, C. H. (2003). Pharmacodynamics of a Novel Des-F(6)-Quinolone, BMS-284756, against Streptococcuspneumoniae in the Thigh Infection Model. Antimicrob. Agents Chemother. 47: 1630-1635 [Abstract] [Full Text]  
  • Zelenitsky, S. A., Ariano, R. E., Iacovides, H., Sun, S., Harding, G. K. M. (2003). AUC0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J Antimicrob Chemother 51: 905-911 [Abstract] [Full Text]  
  • MacGowan, A. P., Rogers, C. A., Holt, H. A., Bowker, K. E. (2003). Activities of Moxifloxacin against, and Emergence of Resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an In Vitro Pharmacokinetic Model. Antimicrob. Agents Chemother. 47: 1088-1095 [Abstract] [Full Text]  
  • MacGowan, A. P., Bowker, K. E. (2003). Mechanism of Fluoroquinolone Resistance Is an Important Factor in Determining the Antimicrobial Effect of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model. Antimicrob. Agents Chemother. 47: 1096-1100 [Abstract] [Full Text]  
  • Jones, R. N., Rubino, C. M., Bhavnani, S. M., Ambrose, P. G. (2003). Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob. Agents Chemother. 47: 292-296 [Abstract] [Full Text]  
  • Ellbogen, M. H., Olsen, K. M., Gentry-Nielsen, M. J., Preheim, L. C. (2003). Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J Antimicrob Chemother 51: 83-91 [Abstract] [Full Text]  
  • Croisier, D., Chavanet, P., Lequeu, C., Ahanou, A., Nierlich, A., Neuwirth, C., Piroth, L., Duong, M., Buisson, M., Portier, H. (2002). Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 50: 349-360 [Abstract] [Full Text]  
  • Zhanel, G. G., Roberts, D., Waltky, A., Laing, N., Nichol, K., Smith, H., Noreddin, A., Bellyou, T., Hoban, D. J. (2002). Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 49: 807-812 [Abstract] [Full Text]  
  • Lister, P. D. (2002). Pharmacodynamics of Gatifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model: Impact of Area under the Curve/MIC Ratios on Eradication. Antimicrob. Agents Chemother. 46: 69-74 [Abstract] [Full Text]  
  • Peterson, M. L., Hovde, L. B., Wright, D. H., Brown, G. H., Hoang, A. D., Rotschafer, J. C. (2002). Pharmacodynamics of Trovafloxacin and Levofloxacin against Bacteroides fragilis in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 46: 203-210 [Abstract] [Full Text]  
  • Ambrose, P. G., Grasela, D. M., Grasela, T. H., Passarell, J., Mayer, H. B., Pierce, P. F. (2001). Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections. Antimicrob. Agents Chemother. 45: 2793-2797 [Abstract] [Full Text]  
  • MacGowan, A. P., Rogers, C. A., Holt, H. A., Wootton, M., Bowker, K. E. (2001). Pharmacodynamics of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model of Infection. Antimicrob. Agents Chemother. 45: 2916-2921 [Abstract] [Full Text]  
  • Malone, R. S., Fish, D. N., Abraham, E., Teitelbaum, I. (2001). Pharmacokinetics of Levofloxacin and Ciprofloxacin during Continuous Renal Replacement Therapy in Critically Ill Patients. Antimicrob. Agents Chemother. 45: 2949-2954 [Abstract] [Full Text]  
  • Mattoes, H. M., Banevicius, M., Li, D., Turley, C., Xuan, D., Nightingale, C. H., Nicolau, D. P. (2001). Pharmacodynamic Assessment of Gatifloxacin against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 2092-2097 [Abstract] [Full Text]  
  • Lister, P. D., Sanders, C. C. (2001). Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 47: 811-818 [Abstract] [Full Text]  
  • Zhanel, G. G., Walters, M., Laing, N., Hoban, D. J. (2001). In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. J Antimicrob Chemother 47: 435-440 [Abstract] [Full Text]  
  • Klepser, M. E., Ernst, E. J., Petzold, C. R., Rhomberg, P., Doern, G. V. (2001). Comparative Bactericidal Activities of Ciprofloxacin, Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against Streptococcus pneumoniae in a Dynamic In Vitro Model. Antimicrob. Agents Chemother. 45: 673-678 [Abstract] [Full Text]  
  • Wright, D. H., Brown, G. H., Peterson, M. L., Rotschafer, J. C. (2000). Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 46: 669-683 [Abstract] [Full Text]  
  • MacGowan, A., Rogers, C., Bowker, K. (2000). The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens. J Antimicrob Chemother 46: 163-170 [Full Text]  
  • Odenholt, I., Cars, T., Lowdin, E. (2000). Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria. J Antimicrob Chemother 46: 35-43 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»